expanded access

More Information on the Expanded Access Trial for Alpharadin (Radium-223)

Radium-223 Chloride (Alpharadin) is now available for the treatment of men with advanced prostate cancer who have symptomatic bone metastases (painful) and who are also castration-resistant (hormone-refractory). This is an expanded access program that will allow the use of Alpharadin prior to the formal FDA approval of the treatment. From the Clinical Trials Web Page [...]

By |2020-02-04T10:11:20-05:00May 20th, 2012|Advanced Prostate Cancer, Alpharadin (radium-223), Bone Metastases, Clinical Trials, Clinical Trials, Pain, Uncategorized|0 Comments
Read More

We Deserve Faster Access to Drugs that Might Extend or Save Our Life

The FDA did introduce its Critical Path initiative in 2004. But, even these expedited processes have become bogged down. The FDA has responded to the political winds and become cautious after the negative publicity it received from the withdrawals of drugs like Rezulin and Vioxx. The best and most recent delay in the prostate cancer [...]

By |2009-06-30T14:50:33-04:00June 30th, 2009|Advanced Prostate Cancer, Advocacy, Drugs & Treatments, FDA, General Information, NIH, Politics of Cancer, Uncategorized|0 Comments
Read More
Go to Top